Advantus Capital Management Inc decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 0.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,517 shares of the company’s stock after selling 99 shares during the period. Advantus Capital Management Inc’s holdings in Zoetis were worth $2,643,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Assetmark Inc. increased its position in Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock worth $102,000 after buying an additional 85 shares during the period. Advisory Services Network LLC bought a new position in Zoetis during the first quarter worth about $112,000. First Interstate Bank increased its position in Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares during the period. Bronfman E.L. Rothschild L.P. increased its position in Zoetis by 15.0% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,570 shares of the company’s stock worth $137,000 after buying an additional 336 shares during the period. Finally, CENTRAL TRUST Co increased its position in Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock worth $142,000 after buying an additional 49 shares during the period. Institutional investors and hedge funds own 98.15% of the company’s stock.
Zoetis Inc. (ZTS) traded up 0.26% on Friday, hitting $62.55. 2,821,302 shares of the stock traded hands. The company’s 50 day moving average price is $60.71 and its 200-day moving average price is $55.32. Zoetis Inc. has a 52-week low of $45.28 and a 52-week high of $63.49. The stock has a market cap of $30.70 billion, a price-to-earnings ratio of 36.37 and a beta of 1.03.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 4th. The company reported $0.53 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.05. The business had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.48 EPS. On average, analysts forecast that Zoetis Inc. will post $2.33 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Thursday, June 15th will be given a dividend of $0.105 per share. The ex-dividend date of this dividend is Tuesday, June 13th. This represents a $0.42 annualized dividend and a dividend yield of 0.67%. Zoetis’s payout ratio is 24.42%.
A number of equities analysts have issued reports on ZTS shares. Argus reiterated a “buy” rating and set a $69.00 price target (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. CL King initiated coverage on Zoetis in a research note on Friday, May 26th. They issued a “buy” rating and a $71.00 target price on the stock. Craig Hallum initiated coverage on Zoetis in a research note on Wednesday, March 15th. They issued a “buy” rating and a $65.00 target price on the stock. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $67.00 target price on the stock in a research note on Wednesday, May 10th. Finally, Jefferies Group LLC boosted their target price on Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $61.39.
In other news, insider Catherine A. Knupp sold 5,785 shares of the firm’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $60.16, for a total transaction of $348,025.60. Following the sale, the insider now directly owns 24,415 shares in the company, valued at approximately $1,468,806.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.31% of the stock is owned by company insiders.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230359/advantus-capital-management-inc-has-2-64-million-position-in-zoetis-inc-zts.html
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.